TTR and amyloidosis: Rapid progress has been made in the treatment of this disease in recent years, and various novel disease‐modifying therapies, including TTR stabilizers and TTR gene‐silencing agents, have shown various levels of clinical benefit by improving multisystem manifestations in patients with ATTRv‐PN.11, 12, 13, 14 These developments introduce a new era in preventing further amyloidosis and facilitating the long‐term stabilization of the disease.